Avian Influenza Vaccine

Global Avian Influenza Vaccine Market to Reach US$1.9 Billion by 2030

The global market for Avian Influenza Vaccine estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Inactivated Vaccine, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$800.9 Million by the end of the analysis period. Growth in the Live Attenuated Vaccine segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$352.5 Million While China is Forecast to Grow at 10.8% CAGR

The Avian Influenza Vaccine market in the U.S. is estimated at US$352.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$402.1 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Avian Influenza Vaccine Market – Key Trends & Drivers Summarized

Why Are Avian Influenza Vaccines Gaining Strategic Relevance in Biosecurity, Poultry Health Management, and Food Supply Stability?
Avian influenza vaccines are emerging as a vital line of defense in global poultry health management as highly pathogenic avian influenza (HPAI) outbreaks continue to disrupt poultry production, cross-border trade, and food security. The escalating frequency and geographic spread of HPAI strains—such as H5N1 and H5N8—have underscored the need for vaccination strategies that go beyond culling and movement restrictions. Vaccines are being viewed not only as a disease control tool but also as a risk mitigation strategy that supports long-term continuity of supply in the global poultry value chain.

The economic losses linked to avian influenza outbreaks are significant, impacting commercial poultry producers, smallholder farms, and national economies reliant on poultry exports. Mass mortality events, reduced egg production, and supply chain disruptions necessitate preemptive disease prevention approaches. Vaccination offers a cost-effective solution that helps preserve flock immunity, minimize transmission, and protect against zoonotic spillover. With growing concerns over pandemic preparedness, governments are beginning to prioritize strategic vaccine stockpiling and targeted immunization programs for high-risk zones.

Moreover, the role of avian influenza vaccines has gained renewed urgency as One Health frameworks emphasize the interconnectedness of animal health, human health, and environmental resilience. Vaccination campaigns are increasingly being integrated with surveillance programs and genetic sequencing to track viral evolution and adapt immunization strategies accordingly. As the poultry sector faces mounting pressure to ensure biosecurity, maintain animal welfare standards, and safeguard protein availability, vaccines are becoming central to the global response infrastructure.

How Are Vaccine Technologies, Strain Matching, and Delivery Platforms Advancing Efficacy and Deployment?
Vaccine development for avian influenza is evolving rapidly, with both inactivated and recombinant technologies gaining prominence. Inactivated whole-virus vaccines remain the most widely used due to their proven safety and broad immunogenicity, particularly in endemic regions. However, newer recombinant vector vaccines—utilizing platforms such as fowlpox, Newcastle disease virus (NDV), and herpesvirus of turkeys (HVT)—are enabling differentiated immune responses, DIVA (Differentiating Infected from Vaccinated Animals) compliance, and easier adaptation to emerging viral strains.

Strain matching remains a critical challenge in vaccine effectiveness, as antigenic drift and reassortment frequently render existing vaccines less protective. Manufacturers are leveraging reverse genetics and genomic surveillance data to accelerate the development of strain-specific or multivalent vaccines. These approaches enable rapid customization and regulatory alignment, particularly in regions prone to variant emergence. Efforts are also underway to develop broad-spectrum or “universal” avian influenza vaccines capable of offering cross-protection against multiple subtypes.

Vaccine delivery platforms are also advancing, with injectable, spray, and in-ovo administration techniques supporting scalable immunization across different poultry species and production systems. Automated delivery systems and thermostable formulations are improving efficiency in large-scale farms, while heat-tolerant, needle-free options are being deployed in resource-limited or remote areas. The integration of vaccination with digital monitoring tools and flock-level immunization analytics is enhancing tracking and compliance in both commercial and government-led programs.

Which Poultry Segments, Production Systems, and Regional Priorities Are Driving Vaccine Demand?
Commercial layer and broiler operations are the primary users of avian influenza vaccines, given their exposure to high-density farming conditions, rapid bird turnover, and economic sensitivity to disease outbreaks. Breeder flocks and grandparent stock are also prioritized for vaccination to maintain supply chain continuity and ensure vertical protection. In contrast, backyard poultry and live bird markets, which often act as reservoirs for viral persistence, are becoming focal points for targeted government interventions and pilot vaccination programs.

Free-range and organic poultry production systems—where birds have outdoor access and higher environmental exposure—are driving increased interest in preventive vaccination. These systems are at higher risk of contact with migratory birds and wild reservoirs, making proactive immunization critical for disease prevention. In regions where culling is politically or economically unviable, such as Southeast Asia, Latin America, and parts of Africa, vaccines are being deployed as a frontline control measure in both commercial and village-level operations.

Regionally, Asia-Pacific continues to lead in avian influenza vaccine consumption due to recurring HPAI outbreaks, dense poultry populations, and longstanding vaccine integration in disease control policies. China, Vietnam, Indonesia, and India have institutionalized vaccine use as part of national biosecurity frameworks. Europe is witnessing renewed adoption amid HPAI resurgence in commercial flocks and wild birds, while North America is cautiously evaluating vaccination alongside enhanced surveillance. Latin America and the Middle East are expanding their vaccination capacity to protect export-oriented poultry sectors and mitigate cross-border transmission risk.

How Are Regulatory Frameworks, Surveillance Synergies, and Trade Considerations Shaping Market Evolution?
Global regulatory agencies, including the OIE (now WOAH) and FAO, are increasingly recognizing the role of vaccines as part of holistic avian influenza management. Countries are implementing risk-based vaccination policies guided by surveillance data, regional risk mapping, and genetic sequencing. Regulatory harmonization, particularly around DIVA-compliant vaccines, is allowing countries to maintain trade transparency while deploying immunization in outbreak-prone zones.

Surveillance and vaccine deployment are becoming interlinked, with integrated systems supporting real-time data collection, serological monitoring, and vaccine impact assessment. Genomic tools are enabling early detection of mutations that may impact vaccine efficacy, prompting timely reformulations. These synergies are helping authorities make informed decisions on vaccination timing, coverage, and withdrawal, minimizing both epidemiological and economic fallout from poorly matched immunization campaigns.

Trade dynamics remain a complex variable in the vaccine equation. Historically, vaccination has triggered export restrictions due to concerns over disease masking and traceability. However, this stance is shifting as science-based frameworks and DIVA strategies gain global traction. Countries are increasingly seeking trade-friendly vaccination protocols that allow for continued market access while ensuring domestic outbreak control. The evolution of trade policy will play a pivotal role in vaccine adoption strategies, particularly for export-reliant poultry economies.

What Role Do Public-Private Partnerships, Emergency Stockpiling, and R&D Pipelines Play in Strengthening Vaccine Readiness?
Public-private partnerships are proving essential in scaling production capacity, improving cold chain logistics, and advancing R&D. Governments are collaborating with animal health companies to secure vaccine stockpiles, accelerate field trials, and build surge manufacturing capability in the event of zoonotic spillover or large-scale outbreaks. These partnerships also facilitate knowledge transfer, regulatory alignment, and joint funding of platform technologies with cross-pathogen utility.

Emergency preparedness is gaining momentum, with countries developing national vaccine banks and outbreak response protocols. Strategic reserves of inactivated and vector-based vaccines are being maintained for rapid deployment in containment zones. Simulation exercises and vaccine distribution drills are enhancing readiness and inter-agency coordination across agriculture, public health, and veterinary sectors. Multilateral initiatives such as the World Bank’s pandemic response frameworks are further integrating avian influenza vaccines into national biosecurity roadmaps.

The R&D pipeline is diversifying, with candidates targeting improved cross-protection, thermostability, and single-dose efficacy. Research is also underway into mRNA-based avian influenza vaccines, leveraging lessons from human vaccine platforms to enhance speed and adaptability. With avian influenza remaining a high-priority zoonosis under One Health mandates, continued investment in vaccine innovation is expected to play a decisive role in global disease preparedness strategies.

What Are the Factors Driving Growth in the Avian Influenza Vaccine Market?
The avian influenza vaccine market is gaining traction as poultry sector vulnerabilities, zoonotic risk awareness, and global food security imperatives converge to reshape disease control priorities. Vaccines are no longer viewed as last-resort tools but as foundational elements of integrated, science-driven animal health management.

Key growth drivers include recurring outbreaks of high-pathogenicity strains, regulatory acceptance of vaccination in trade-sensitive contexts, technological advancements in strain-matched and DIVA-compliant formulations, and expanding poultry production in high-risk regions. Public sector readiness initiatives and private sector R&D efforts are jointly reinforcing market momentum across geographies and poultry types.

As avian influenza evolves under migratory, agricultural, and climatic pressures, could vaccine-enabled resilience redefine how the world safeguards poultry supply chains and prepares for the next zoonotic frontier?

SCOPE OF STUDY:

The report analyzes the Avian Influenza Vaccine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Inactivated, Live Attenuated, Recombinant, Vector-based, Other Types); Application (Chicken, Duck, Goose, Turkey, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• AstraZeneca
• Bayer AG
• Bimeda Inc.
• Boehringer Ingelheim GmbH
• Ceva Santé Animale
• CSL Seqirus
• Elanco Animal Health
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc (GSK)
• HIPRA
• ID Biomedical Corporation
• Johnson & Johnson
• Mallinckrodt Pharmaceuticals
• Medion
• Merck & Co., Inc.
• Microgen
• Moderna, Inc.
• Novartis AG
• Novavax, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.